ArticleInternational journal of cancer2022

Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study.

Min Jin Ha et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.